Everything you need to learn about The Reversal Initiative. Research impact, assets, and direct contact information.
The Reversal Initiative is a self-funded, open-source project building AI-powered computational drug discovery tools to fight Alzheimer's disease. Founded by David Scott Lewis (former META EVP, 20+ peer-reviewed papers) and Enrique Zueco (CTO, AI-Scientist v2 architect), the initiative provides 37+ production-ready modules for researchers worldwide.
The project was inspired by a January 2026 Cell Reports Medicine paper (DOI: 10.1016/j.xcrm.2025.102535) demonstrating that P7C3-A20, an NAD+ pathway activator, reversed Alzheimer's pathology in mice. The Reversal Initiative builds the computational bridge between this preclinical breakthrough and potential human therapies.
The team has published 23+ peer-reviewed papers and presented at AAAI-26, NeurIPS, and IROS. The platform runs on standard hardware and is designed for researchers who cannot afford commercial computational platforms.
A tech executive's mother died from Alzheimer's. His sister was diagnosed 18 months ago. Now he's building the tools he wishes existed.
Scientists reversed Alzheimer's in mice. An AI team is building the open-source bridge to human therapies using 37+ computational modules.
Open-source tools that democratize drug discovery. Any researcher, anywhere, can screen molecules against Alzheimer's targets at no cost.
Why locking research tools behind $500K paywalls slows down the fight against the world's most costly disease.
How AI and open-source code could give every lab in the world access to tools that were once reserved for big pharma.
High-resolution founder photos and team imagery (coming soon)
Initiative and AIXC logos in SVG, PNG, and EPS formats (coming soon)
Single-page summary with key facts and figures (coming soon)
For interviews, comments, or additional information:
We typically respond to press inquiries within 12 hours.
Get the complete media package including high-res assets, fact sheet, founder bios, and interview availability.
Request Press Kit